• Barros P, Martinez-Giralt X. 2008. On international cost-sharing of pharmaceutical R&D. International Journal of Health Care Finance and Economics 8: 301312.
  • Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. 2008. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336: 251254.
  • Danzon P. 1997. Price discrimination for pharmaceuticals: welfare effects in the US and EU. International Journal of the Economics of Business 4(3): 301321.
  • Danzon P, Taylor E. 2010. Drug pricing and value in oncology. The Oncologist 15(1): 2431.
  • Danzon P, Towse A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics 3: 183205.
  • Danzon P, Mulcahy A, Towse A. 2011. Pharmaceutical prices in emerging markets: effects of income, competition and procurement. NBER Working Paper 17174. Cambridge, MA.
  • Danzon P, Towse A, Mestre-Ferrendiz J. 2012. Value-based differential pricing: efficient prices for drugs in a global context. NBER Working Paper No. 18593. Cambridge, MA.
  • Flynn S, Hollis A, Palmedo M. 2009. An economic justification for open access to essential medicine patents in developing countries. The Journal of Law, Medicine & Ethics 37(2): 184208.
  • Garber A, Phelps C. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16: 131.
  • Garber A, Jones C, Romer P. 2006. Insurance and incentives for medical innovation. Forum for Health Economics and Policy: Vol.9: Iss.2 (Biomedical Research and the Economy, Article 4.
  • Jack W, Lanjouw J. 2005. Financing pharmaceutical innovation: how much should poor countries contribute? The World Bank Economic Review 19(1): 4567.
  • Jena A, Philipson T. 2008. Cost effectiveness analysis and innovation. Journal of Health Economics 27: 12241236.
  • Jena A, Philipson T. 2013. Endogenous cost-effectiveness analysis and health care technology adoption. Journal of Health Economics 32: 172180.
  • Lakdawalla D, Sood N. 2009. Innovation and the welfare effects of public drug insurance. Journal of Public Economics 93: 541548.
  • Malueg D, Schwartz M. 1994. Parallel imports, demand dispersion, and international price discrimination. Journal of International Economics 37: 167195.
  • National Institute for Health and Clinical Excellence. 2009. Appraising life-extending, end of life treatments. National Institute for Health and Clinical Excellence. Available from: Accessed on 1st July 2013.
  • Office of Fair Trading. 2007. The Pharmaceutical Price Regulation Scheme: An OFT Market Study. OFT: London.